CFM
COGT icon

Catalyst Funds Management’s Cogent Biosciences COGT Stock Holding History

Catalyst Funds Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,600
Closed -$190K – 528
2024
Q3 		$190K Hold
17,600
– – 0.04% 305
2024
Q2 		$148K Buy
+17,600
New +$133K 0.04% 233

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Catalyst Funds Management's COGT Position: Q4 2024 in Review

Catalyst Funds Management sold out of Cogent Biosciences (COGT) in Q4 2024, closing a stake of 17,600 shares — an estimated $190K sold.

Catalyst Funds Management first reported a position in COGT in Q2 2024 and held it in 2 quarters. The position peaked at $190K in Q3 2024. 176 funds tracked by Wall St. Rank hold COGT as of Q4 2024.

  • Catalyst Funds Management reported no remaining Cogent Biosciences position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 17,600 Cogent Biosciences shares in Q4 2024, an estimated $190K.
  • Catalyst Funds Management first reported a position in Cogent Biosciences in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Cogent Biosciences position peaked at $190K in Q3 2024.
  • 176 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.